Yazılar

Merck Shares Fall 9% Despite Earnings Beat and Strong Demand for Key Drugs

/in /tarafından

Merck reported second-quarter revenue and adjusted earnings that exceeded Wall Street’s expectations, driven by strong sales from its blockbuster cancer drug Keytruda and other treatments in its oncology and vaccines portfolios, as well as a newly launched cardiovascular drug. Despite this, Merck’s shares fell by 9% due to lighter-than-expected sales of Gardasil, a vaccine for HPV, exacerbated by shipment issues in China.

Merck raised its full-year sales forecast to $63.4 billion to $64.4 billion, slightly up from its previous guidance of $63.1 billion to $64.3 billion. However, it lowered its adjusted profit guidance to a range of $7.94 to $8.04 per share, down from $8.53 to $8.65 per share, reflecting one-time charges for its acquisitions of Harpoon Therapeutics and EyeBio.

For the second quarter, Merck reported adjusted earnings per share of $2.28, surpassing the expected $2.15, and revenue of $16.11 billion, above the anticipated $15.84 billion. The company posted a net income of $5.46 billion, or $2.14 per share, compared to a net loss of $5.98 billion, or $2.35 per share, in the same period last year.

Keytruda recorded $7.27 billion in revenue, up 16% year-over-year, driven by higher uptake for earlier-stage cancers and strong demand for metastatic cancers. Gardasil sales increased by only 1% to $2.48 billion due to shipment timing issues in China. Winrevair, approved in March for treating a progressive lung condition, posted $70 million in revenue, while Capvaxive, a newly approved pneumococcal vaccine, is expected to drive future growth.

Merck’s pharmaceutical division saw a 7% increase in revenue to $14.41 billion. The company’s Type 2 diabetes treatment, Januvia, faced a 27% decline in sales to $629 million due to lower demand, prices, and generic competition. Sales of Merck’s Covid antiviral pill, Lagevrio, fell by 46% to $110 million but still exceeded expectations.

Merck’s animal health division reported $1.48 billion in sales, up 2% from the previous year, but slightly below analyst expectations. Despite strong overall performance, investor concerns about Gardasil sales and future challenges in the pharmaceutical landscape influenced the decline in Merck’s stock.

23andMe CEO Anne Wojcicki Proposes to Take Company Private as Stock Plummets

/in /tarafından

Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private, as its stock price remains below $1. In a filing with the U.S. Securities and Exchange Commission on Wednesday, Wojcicki offered to buy all outstanding shares of 23andMe’s common stock for 40 cents per share in cash. This proposed price represents an 11% premium to the company’s closing stock price in April.

Wojcicki, who co-founded 23andMe in 2006, initially expressed interest in acquiring the company in April, stating that she would not support any alternative transaction. She aims to complete the transaction “as promptly as possible,” according to the filing. On Wednesday, shares of 23andMe closed at 40 cents.

23andMe, known for its at-home DNA testing kits that provide customers with insights into their ancestry and genetic profiles, went public in 2021 through a merger with a special purpose acquisition company (SPAC), valuing it at approximately $3.5 billion. However, the company has struggled to maintain steady revenue, as customers only need to use its DNA testing product once. Since its public debut, the stock has declined by over 95%.

Wojcicki believes that taking 23andMe private will better equip the company to focus on its long-term mission without the short-term pressures of the public markets. In November, the company received a deficiency letter from the Nasdaq Listing Qualifications Department, giving it 180 days to bring its share price back above $1. In response, 23andMe’s board formed a “Special Committee” in late March to explore options to improve the stock price.

The Special Committee will need to approve or reject Wojcicki’s proposal to take the company private.

Berkshire Halves Apple Stake, Boosts Cash to $277 Billion as it Gets ‘Defensive’

/in /tarafından

Warren Buffett’s Berkshire Hathaway has significantly increased its cash reserves to nearly $277 billion, while also selling about half of its stake in Apple. This move suggests that Buffett, at 93 years old, is becoming cautious about the broader U.S. economy and potentially overvalued stock market. The company’s results were released after a global stock market selloff, with the Nasdaq entering correction territory and a weak jobs report raising concerns about U.S. economic activity.

Cathy Seifert, an analyst at CFRA Research, interprets Berkshire’s actions as defensive, highlighting the conglomerate’s growing cash stake and reduced stock investments. As of June 30, Berkshire’s cash reserves increased from $189 billion three months earlier, largely due to selling $75.5 billion worth of stocks. Notably, Berkshire sold around 390 million Apple shares in the second quarter, on top of 115 million sold earlier in the year, as Apple’s stock price increased by 23%. Despite these sales, Berkshire still owns about 400 million Apple shares valued at $84.2 billion.

This marked the seventh consecutive quarter in which Berkshire sold more stocks than it purchased. Additionally, Berkshire repurchased only $345 million of its own stock, down significantly from $2.57 billion in the first quarter. Jim Shanahan, an analyst at Edward Jones, noted that Buffett’s reluctance to invest in publicly traded stocks, including Berkshire’s own, raises concerns about his outlook on the markets and economy.

Financial Performance and Strategic Moves

Berkshire’s second-quarter profit from its diverse businesses increased by 15% to $11.6 billion, with substantial contributions from its insurance businesses, including Geico. However, overall revenue saw only a modest 1% rise to $93.65 billion, with notable declines in sectors such as auto dealerships and the Pilot truck stop chain.

The conglomerate’s earnings were buoyed by short-term Treasury returns, which might decline once rate cuts begin. Shanahan suggested that revenue challenges could make it difficult for Berkshire to sustain earnings growth into 2025. Quarterly net income fell 15% to $30.34 billion due to stock price fluctuations affecting Berkshire’s investment values.

Buffett has consistently advised shareholders to disregard quarterly investment gains and losses due to their volatility. Despite substantial cash reserves, Berkshire often accumulates cash when it cannot find attractive investment opportunities. Since mid-July, the company has also sold over $3.8 billion in Bank of America shares, its second-largest stock holding.

Buffett emphasized the importance of making low-risk investments with potential for significant returns. He expects Apple to remain Berkshire’s largest stock investment, although selling shares made sense to mitigate tax implications.

Impact on Key Businesses

Berkshire’s second-quarter results showed mixed performance across its various sectors. Profit at BNSF railroad declined by 3%, affected by legal expenses despite lower operating costs and increased shipping volumes. Berkshire Hathaway Energy’s profit fell by 17%, partly due to lawsuits against its PacifiCorp utility unit, which is blamed for causing wildfires in Oregon in 2020.

Despite these challenges, Berkshire’s Class A shares have performed well, closing at $641,435 on Friday, up 18% for the year, compared to a 12% increase in the S&P 500. As Buffett approaches 60 years of leading Berkshire, Vice Chairman Greg Abel is anticipated to succeed him as CEO.